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Abstract 
The phosphatase and tensin homolog located on chromosome ten, PTEN, is one of the most commonly mutated tumor suppressor 
genes (TSGs) in human cancer [1–3]. PTEN catalyzes the conversion of the membrane lipid second messenger PIP3 to PIP2 and is 
therefore a key mediator of the AKT/PKB pathway [4,5]. Although inherited PTEN mutations predispose to the development of Cowden 
syndrome, which is also a breast cancer susceptibility syndrome, the role of PTEN in breast tumorigenesis has been considered minor 
when compared to that of other TSGs such as BRCA1 or p53 [6]. There is no current evidence that mutations in PTEN account for a 
substantial proportion of familial breast cancer in the absence of Cowden syndrome [6]. Moreover, PTEN mutations or deletions are not 
common in sporadic breast tumors, especially when compared with other tumor types (<5%) such as prostate cancer [7, 8].
Despite this evidence, recent studies have demonstrated that PTEN protein down-regulation is frequently observed (more than 50%) in 
sporadic breast tumors, highlighting the relevance of the dose of this TSG for the pathogenesis of breast cancer [7–9]. Our paper, in the 
last month’s issue of Nature Genetics provides additional evidence of the role of PTEN dose in breast cancer susceptibility, braking 
current dogmas regarding the development of cancer and opening to novel clinical and therapeutic implications [10]. 
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Challenging the Two Hit hypothesis of 
tumorigenesis 
For students that, like myself, attended medical school in the 
mid 1990s, it was often unclear, with few exceptions, how novel 
discoveries in cancer genetics could impact on the clinic. At that 
time, the mechanism driving tumor initiation and cancer 
progression was reasonably clear. One of the first lessons in the 
class of cancer genetics included the explanation and 
discussion of the well known Knudson’s two-hit model of 
tumorigenesis [11]. Knudson envisioned tumor suppression as a 
recessive trait, whereby an inactivating mutation present at birth 
is accompanied by a second somatic loss in the tumor.  His 
findings in patients affected with retinoblastoma were entirely in 
agreement with his proposed model of tumorigenesis [11].  As a 
result of this visionary working model, a number of TSGs that 
undergo bi-allelic disruption or truncating point mutations were 
identified.  Only later, in the era of mouse genetics was it 
demonstrated that for some TSGs such as p53 even 
inactivation of a single allele of the TSG would have been 
sufficient to initiate and promote tumorigenesis [12]. The genes 
that behave as p53 were named “haploinsufficient” tumor 
suppressor genes. 
In our recent paper in Nature Genetics, we push further the 
concept of haploinsufficiency demonstrating that even subtle 
changes in the level of PTEN can significantly increase the 
chance of developing breast cancer [10]. Mice with Pten 
expression below 20% the normal expression levels develop 
breast tumors in absence of additional mutations or loss of 
heterozigosity (LOH) in the Pten alleles [10]. Importantly, this 
subtle reduction in Pten levels initiate breast cancer 
susceptibility without consequence for other tissues including 
the prostate epithelium [10]. On this line, we observed that the 
progressive reduction of Pten levels in the mouse population 
was associated with the development of highly aggressive 
breast tumors and with the appearance of additional tumor 
phenotypes [10]. Mice born with 50% of Pten levels (Pten
+/-) 
develop basal like breast cancers at higher frequency than mice 
born with 80% of Pten (Pten
hy/+) (Fig.2). In addition, Pten
+/- mice 
developed prostatic intraepithelial neoplasia and uterine cancer, 
which we did not observe in the Pten
hy/+ population [10]. This 
suggests that some tissues can be more susceptible than 
others to minimal variations of Pten levels and worn us on the 
relevance of gene doses rather than gene mutations for cancer 
initiation and progression. Our study adds another dimension to 
the “Knudsonian model of tumorigenesis” demonstrating that
cancer susceptibility can be driven by a progressive —but 
slight—continuum reduction in tumor suppressor levels. This 
implies that any factors — chemicals, diet, and other 
carcinogens— which affect the level of a TSG without affecting 
its genetic structure are potential “pro-oncogenic” factors. In our 
paper, we propose a continuum working model for cancer 
initiation in which subtle variations in the expression of TSGs 
have a profound impact on cancer susceptibility [11] (Fig. 1). 
This model differs from previous models of tumorigenesis which 
imply the progressive accumulation of mutations in a “saltatory” 
manner.  
 
Clinical and therapeutic implications of 
PTEN dose 
PTEN deficiency not only drives breast cancer tumorigenesis 
but also confers resistance to targeted therapy with 
trastuzumab, a humanized monoclonal antibody against ErbB2 
(also referred to as HER2/neu). Trastuzumab is the most 
effective treatment offered to metastatic breast cancer patients 
with HER2 over expression [9]. Binding to the ErbB2 receptor, 
Trastuzumab stabilizes and activates the tumor suppressor 
PTEN and consequently down-regulates the PI3K–Akt signaling 
pathway. When PTEN levels are down-regulated the effects of 
trastuzumab are impaired and the outcome and prognosis of 
patients decrease [9]. Our previous and recent findings further 
demonstrate that PTEN protein down-regulation leads to the 
development of basal-like breast tumors [8].  This tumor 
phenotype is  associated with aggressive behavior, poor 
prognosis, and tumors typically lacking in the expression of 
hormone receptors or HER-2 ("triple-negative" phenotype) [8]. 
Thus, patients with basal-like cancers are unlikely to benefit 
from trastuzumab treatment, as well as from hormonal and 
conventional chemotherapy. 
Despite this evidence, the assessment of PTEN status in breast 
cancer patients undergoing treatment with targeted or 
conventional therapy is still not commonly recommended by 
clinicians. Indeed, the percentage of patients with PTEN 
mutations is low and not sufficient to justify screening for PTEN 
mutations/deletions. In addition, the determination of PTEN 
protein levels depends on the reliability of PTEN 
immunohistochemistry and the ability of the pathologists. 
Our novel findings suggest that subtle variations in PTEN 
expression may also influence the outcome of patient 
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Figure 1: Implications for tumorigenesis upon subtle reduction of TSG levels.  The ‘no hits’ model of cancer susceptibility. The rectangular 
green box represents a functional allele of a given TSG. The rectangular red box represents a nonfunctional allele inactivated by, for example, 
mutation or deletion. The rectangular green, yellow and red box represents an allele of a TSG whose expression is reduced below the normal 
levels. The black rectangle represents a genetic hit. Note that the model represented does not exclude the presence of additional hits on other 
loci.
treatments and point to the assessment of PTEN expression 
rather that PTEN mutations or protein determination in patients 
undergoing targeted or conventional treatments [10] (Fig.2).   
Interestingly, in our paper we show that in all the patients 
affected with basal like- breast tumors, PTEN expression is 
down-regulated when compared to controls [10]. Moreover, we 
demonstrate that the immunohistochemistry for PTEN is not a 
reliable means to identify subtle variations of PTEN in tumor. 
Samples where PTEN expression was subtly down-regulated 
scored positive on the immunohistochemistry and it was not 
possible to discriminate between controls and tumor samples 
with moderate/slight decrease in PTEN [10]. Therefore, it is 
possible to hypothesize that, previous studies where PTEN 
levels were evaluated by immunohistochemistry have 
underestimated the role of this TSG in predicting the outcome of
cancer therapy. Hence, highly quantitative combinatorial 
methods for integrating genomic and proteomic information are 
required to precisely determine the impact of such subtle down-
regulations in PTEN expression on both targeted and 
individualized approaches for cancer therapy. We believe that a 
positive future development of our findings will be the 
identification of genetic factors or novel PTEN interacting 
proteins, which affecting directly or indirectly the level of PTEN 
expression may initiate breast cancers predisposition or affect 
the outcome of cancer therapy. An example of this could be the 
identification of single nucleotide polymorphisms in the promoter 
of PTEN or the discovery of negative regulators of the 
transcription or degradation of this TSG. This may lead to the 
development of novel genetic tests for the screening of subjects 
with high breast cancer risk or that may be used to predict the 
outcome of cancer therapy. 
 3  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2010, 4:192 
 
 
Figure 2: Correlation between PTEN levels, incidence of basal-like breast tumors and treatment resistance. Note that the progressive reduction 
of PTEN levels is inversely correlated with the incidence of basal like breast tumors.
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